News | October 31, 2023
Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Subscribe To Our Newsletter & Stay Updated
